Cue Biopharma Inc
1UC
Company Profile
Business description
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Contact
40 Guest Street
BostonMA02135
USAT: +1 617 949-2680
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
41
Stocks News & Analysis
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
We plan to raise our fair value estimate of BlackRock stock.
stocks
Our view of ANZ’s strategic plan
Trying to please customers and shareholders with a simpler and leaner bank.
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,299.00 | 21.90 | 0.24% |
| CAC 40 | 8,077.00 | 157.38 | 1.99% |
| DAX 40 | 24,181.37 | 55.57 | -0.23% |
| Dow JONES (US) | 46,253.31 | 17.15 | -0.04% |
| FTSE 100 | 9,424.75 | 28.02 | -0.30% |
| HKSE | 25,910.60 | 469.25 | 1.84% |
| NASDAQ | 22,670.08 | 148.38 | 0.66% |
| Nikkei 225 | 47,672.67 | 825.35 | 1.76% |
| NZX 50 Index | 13,282.31 | 25.09 | -0.19% |
| S&P 500 | 6,671.06 | 26.75 | 0.40% |
| S&P/ASX 200 | 8,990.90 | 22.20 | 0.25% |
| SSE Composite Index | 3,912.21 | 46.98 | 1.22% |